Passive Antibody-Mediated Immunotherapy for the Treatment of Malignant Gliomas

Siddhartha Mitra, Gordon Li, Griffith R. Harsh IV

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations

Abstract

Despite advances in understanding the molecular mechanisms of brain cancer, the outcome of patients with malignant gliomas treated according to the current standard of care remains poor. Novel therapies are needed, and immunotherapy has emerged with great promise. The diffuse infiltration of malignant gliomas is a major challenge to effective treatment; immunotherapy has the advantage of accessing the entire brain with specificity for tumor cells. Therapeutic immune approaches include cytokine therapy, passive immunotherapy, and active immunotherapy. Cytokine therapy involves the administration of immunomodulatory cytokines to activate the immune system. Active immunotherapy is the generation or augmentation of an immune response, typically by vaccination against tumor antigens. Passive immunotherapy connotes either adoptive therapy, in which tumor-specific immune cells are expanded ex vivo and reintroduced into the patient, or passive antibody-mediated therapy. In this article, the authors discuss the preclinical and clinical studies that have used passive antibody-mediated immunotherapy, otherwise known as serotherapy, for the treatment of malignant gliomas.

Original languageEnglish (US)
Pages (from-to)67-76
Number of pages10
JournalNeurosurgery Clinics of North America
Volume21
Issue number1
DOIs
StatePublished - Jan 2010
Externally publishedYes

Keywords

  • Bevacizumab
  • Epidermal growth factor receptor
  • Epidermal growth factor receptor variant III
  • Glioblastoma multiforme
  • Monoclonal antibody
  • Tenascin-C

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Passive Antibody-Mediated Immunotherapy for the Treatment of Malignant Gliomas'. Together they form a unique fingerprint.

Cite this